Skip Ribbon Commands Skip to main content
Dog Arthrosis > Publications

Publications

Table of Contents

publication
Efficacy of Firocoxib in Preventing Urate-Induced Synovitis, Pain, and Inflammation in Dog

Marlene Drag, DVM, MS, DACLAM. Bruce N. Kunkle, DVM, MS, PhD. Davida Romano, MPH. Peter D. Hanson, DVM, PhD, DACVS. Veterinary Therapeutics, 2007, Vol. 8, No. 1, Spring 2007

http://vetlearn.com/ArticleDetails/tabid/106/ArticleID/3615/Default.aspx

Abstract

This positive-control study evaluated the efficacy of firocoxib versus carprofen, deracoxib, and meloxicam for the prevention of pain and inflammation in a urate crystal synovitis model of lameness. Lameness scoring and force plate gait analysis were used to assess efficacy. The resulting lameness scores and force plate ground reaction forces after urate crystal injection were not significantly different among the groups. Relative to each group’s baseline (nonlame) score, only the firocoxib group was not significantly lame, based on lameness score, at the model’s peak effect.

Table of Contents

publication
Efficacy and Safety of Firocoxib in the Management of Canine Osteoarthritis under Field Conditions

P. D. Hanson, K. C. Brooks, J. Case, M. Conzemius, W. Gordon, J. Schuessler, B. Shelley, R. Sifferman, M. Drag, R. Alva, L. Bell, D. Romano, and C. Fleishman Veterinary Therapeutics, 2006, Vol. 7, No. 2, Summer 2006

http://vetlearn.com/ArticleDetails/tabid/106/ArticleID/1594/Default.aspx

Abstract

A total of 249 client-owned dogs with osteoarthritis were treated with firocoxib (5 mg/kg/day) or a positive control, etodolac (10–15 mg/kg/day), for 30 days. Veterinary examinations were performed on approximately days 0 (visit 1), 14 (visit 2), and 29 (visit 3). Based on defined noninferiority criteria, firocoxib and etodolac were comparable. Based on the magnitude of the change from baseline, improvement with firocoxib was significantly greater than with etodolac for lameness at a trot (visits 2 and 3) and for lameness at a walk, pain on manipulation, and range of motion (visit 3) (P < .05). In weekly owner evaluations, firocoxib provided significantly greater improvement than etodolac (P < .05) at each scoring.

Table of Contents

publication
Tolerance of firocoxib in dogs with osteoarthritis during 90 days

O. Lecoindre, C. Pepin-Richard J. vet. Pharmacol. Therap., 2010, doi: 10.1111/j.1365-2885.2010.01227.x

Abstract

The gastrointestinal and renal tolerance of firocoxib was evaluated during a study conducted in a clinical setting. Sixteen elderly dogs were treated for osteoarthritis with firocoxib tablets (Previcox®), for a period of three months. Clinical examination, clinical chemistry, urinary and endoscopic measurements were carried out in dogs on days (D) 0, 30 and 90. Clinical scores improved significantly from D0 to D30 and between D0 and D90. No significant changes in renal values were reported throughout the study. Endoscopic evaluation showed that the treatment had no effect on the endoscopic scores. The results confirmed the safety of the long-term treatment with firocoxib, even in elderly, at-risk dogs and its efficacy as a long-term pain management in case of osteoarthritis.

Table of Contents

publication
Clinical evaluation of firocoxib and carprofen for the treatment of dogs with osteoarthritis

M. Pollmeier, C. Toulemonde, C. Fleishman, P. D. Hanson Veterinary Record, 2006, (2006) 159, 547-551

Abstract

A double-blind, randomised, controlled, multicentre field study was conducted to compare the safety and efficacy of firocoxib chewable tablets and carprofen tablets in 218 dogs with osteoarthritis. Firocoxib is a non-steroidal anti-inflammatory drug with more than 350-fold selectivity in dogs for the inducible isoform of the enzyme cyclo-oxygenase-2. The efficacy, tolerance and ease of administration of firocoxib (5 mg/kg/ day) and carprofen (4 mg/kg/day) were assessed by the owners and the attending veterinarians during 30 days of treatment. The efficacy was assessed in terms of the dogs’ overall scores at the end of the treatment, based on the veterinarians’ assessment of lameness, pain on manipulation/palpation, range of motion, and joint swelling; 92,5 per cent of the dogs treated with firocoxib and 92,4 percent of the dogs treated with carprofen had improved. The reduction in lameness in the dogs treated with firocoxib was significantly greater than in the dogs treated with carprofen. The owners' evaluations were that 96,2 percent of the dogs treated with firocoxib and 92,4 percent of the dogs treated with carprofen had improved, and this difference was statistically significant.

Table of Contents

publication
Clinical Effectiveness and Safety of a New NSAID, Firocoxib: A 1,000 Dog Study

William G. Ryan, BVSc, MBA, MRCVS. Katherine Moldave, MBA. Doug Carithers, DVM, EVP. Veterinary Therapeutics, 2006, Vol. 8, No. 4, Winter 2007

http://vetlearn.com/ArticleDetails/tabid/106/ArticleID/1556/Default.aspx

Abstract

For the Previcox (firocoxib, Merial) Experience Trial, practicing veterinarians across the United States were asked to enroll dogs diagnosed with osteoarthritis. At an initial visit, owners of dogs deemed suitable for NSAID therapy were given Previcox and instructed to maintain a daily diary and to return 10 and 40 days after treatment began. Approximately 86% of 1,002 enrolled dogs completed the study. The withdrawal rate associated with gastrointestinal side effects was low (2.9% of dogs), and no serious drug-related adverse events were reported. Investigators and owners rated 93% and 91% of dogs, respectively, as improved, and 86% of owners rated their dogs “happier” or “more active” after treatment with firocoxib. The improvements observed following initiation of firocoxib therapy were independent of gender, breed, starting body weight, age, and prior NSAID use. These results support previous findings that firocoxib is well tolerated and effective when used under field conditions.

Table of Contents

publication
Switching NSAIDs in Practice: Insights from the Previcox (Firocoxib) Experience Trial

William G. Ryan, BVSc, MBA, MRCVS. Katherine Moldave, MBA. Doug Carithers, DVM, EVP. Veterinary Therapeutics, 2007, Vol. 8, No. 4, Winter 2007

http://vetlearn.com/ArticleDetails/tabid/106/ArticleID/3694/Default.aspx

Abstract

Veterinarians currently have a choice of six registered NSAIDs for use in the management of canine osteoarthritis. There is a need for data to clarify whether there is an increased risk of side effects occurring in the event of a switch between different members of the NSAID class. In this retrospective analysis of extensive data collected in the 1,000 dog Previcox (firocoxib, Merial) Experience Trial, the incidence of side effects in dogs reported as treated with an NSAID 7 days or less before enrollment was compared with that in dogs reported as not having received an NSAID in the equivalent period. Statistical analysis of the data indicates that observation of an interval of up to 1 week between beginning treatment with firocoxib and cessation of treatment with a different NSAID was not associated with any increased risk of adverse events.

Table of Contents

publication
Evaluation of the adverse effects of oral firocoxib in healthy dogs

P.V.M. Steagall, F.B. Mantovani, T.H. Ferreira, E.S. Salcedo, F.Q. Moutinho, S.P.L. Luna J. vet. Pharmacol. Therap., 2007, 30, 218–223, doi: 10.1111/j.1365-2885.2007.00842.x.

Abstract

This study evaluated the adverse effects of oral firocoxib in dogs. Six dogs (20.2 ± 6.3 kg) were studied. Values for complete blood count (CBC), serum urea, creatinine, alanine transaminase, alanine phosphatase, c-glutamyl transferase, occult blood in feces, platelet aggregation, and buccal mucosal bleeding time were measured before and 7, 14, 21, and 29 days after SID treatment with firocoxib 5.3 ± 0.34 mg/kg (FG) or lactose 1 mg/kg (LG) for 28 days, in a randomized crossover study. Gastrointestinal (GI) tract endoscopy was performed before treatment began and at 29 days. Lesions were scored from grade 0 to 6. Data were analyzed using ANOVA and paired t-tests (P < 0.05). None of the dogs presented adverse clinical effects. There were no significant changes in CBC, biochemical profiles within groups, or differences between groups. Pretreatment mean ± SD bleeding time (LG, 70.7 ± 32.1 sec; FG, 75.8 ± 38.1 sec) and platelet aggregation (LG, 86.4 ± 10.2%; FG, 85.6 ± 9.2%) were not significantly different from readings at 29 days (LG, 95.2 ± 25 sec; FG, 91.7 ± 24 sec and LG, 73.2 ± 15.1%; FG, 84 ± 10.3%) nor the groups were different. None of the dogs had positive fecal occult blood tests, and endoscopic lesion scores were grade 0 both before treatment and at 29 days. Administration of firocoxib did not cause any adverse effects on GI, or hematological or serum biochemical variables and appears to have been well tolerated by dogs.

Table of Contents

publication
Comparison of the effects of firocoxib, carprofen and vedaprofen in a sodium urate crystal induced synovitis model of arthritis in dogs.

Herman A.W. Hazewinkel, Walter E. van den Brom, Lars F.H. Theyse, Matthias Pollmeier, Peter D. Hanson Research in Veterinary Science 84 (2008) 74-79

http://www.sciencedirect.com/

Abstract

A randomized, placebo-controlled, four-period cross-over laboratory study involving eight dogs was conducted to confirm the effective analgesic dose of firocoxib, a selective COX-2 inhibitor, in a synovitis model of arthritis. Firocoxib was compared to vedaprofen and carprofen, and the effect, defined as a change in weight bearing measured via peak ground reaction, was evaluated at treatment dose levels. A lameness score on a five point scale was also assigned to the affected limb. Peak vertical ground reaction force was considered to be the most relevant measurement in this study. The firocoxib treatment group performed significantly better than placebo at the 3 h post-treatment time point and significantly better than placebo and carprofen at the 7 h post-treatment time point. Improvement in lameness score was also significantly better in the dogs treated with firocoxib than placebo and carprofen at both the 3 and 7 h post-treatment time points.

Table of Contents

publication
Long-term efficacy and safety of firocoxib in the treatment of dogs with osteoarthritis

A. Autefage, F. M. Palissier, E. Asimus, C. Pepin-Richard Veterinary Record doi: 10.1136/vr.d1456 - June 3, 2011

http://veterinaryrecord.bmj.com/content/168/23/617.abstract

Abstract

Thirty-nine client-owned dogs with osteoarthritis were treated with 5 mg/kg firocoxib administered orally, once a day for 52 weeks. Veterinary examinations were performed on approximately days 0, 15, 90, 180, 270 and 360. Twenty-five dogs completed the study. The withdrawal rate associated with gastrointestinal side effects was low (5.1 per cent of dogs). Based on the owners' assessment, 82 per cent of the dogs had improved at day 15, 84 per cent of the 32 remaining dogs had improved at day 90, and 96 per cent of the 25 dogs that completed the trial had improved at day 360. During this trial, 12 (48 per cent) of the 25 remaining dogs showed an improvement in their lameness from day 90 to day 360 (P<0.05).

Table of Contents